ArticleNeuroimage. Reports2025
Mapping of neuronal redox conditions in a mouse model of Rett syndrome.
Article in Neuroimage. Reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Live Visualization of Endoplasmic Reticulum Redox Potential in Zebrafish Embryos Reveals Region-Specific Heterogeneity.Biomedicines · 2026Article
- Metformin Treatment Shows Beneficial Effects on RTT-Associated Phenotypical Deficits inPharmaceuticals (Basel, Switzerland) · 2026Article
- Recent advances in epigenetic therapeutics for Rett syndrome: from mechanisms to clinical trials.Frontiers in behavioral neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rett syndrome (RTT) is associated with a systemic redox imbalance, potentially provoking cellular dysfunction and contributing to some of the disease symptoms. While previous studies have reported these redox alterations also in brain, the exact cerebral redox pattern remains unclear. We therefore generated MeCP2-deficient mice expressing the cytosolic redox sensor roGFPc in excitatory projection neurons. Taking advantage of the earlier developed excitation ratiometric 2-photon imaging, we mapped the redox conditions of individual hippocampal and cortical neurons in acute brain tissue slices of female mice. These quantitative redox analyses revealed clear brain-regional differences in the degree of roGFPc oxidation, with dentate gyrus and CA3 being most oxidized, CA1 being least oxidized and cortical areas presenting intermediate oxidation levels. On postnatal day p50, hardly any RTT-related differences were evident. With maturation (>p100), redox conditions became more reducing in WT females. This was, however, not the case in MeCP2-deficient females, whose hippocampal and especially cortical neurons now appeared clearly more oxidized. By correlative redox microscopy, we succeeded to relate cellular redox-conditions to cellular MeCP2 expression. Validation in CA1 and somatosensory cortex revealed that, based on improved discrimination sensitivity, a more oxidized redox balance became detectable in MeCP2-deficient cortical neurons already on p50. Expression of a mitochondrial catalase efficiently abolished the more oxidizing redox milieu in MeCP2-deficient cortical neurons. This confirms a widespread oxidative burden in forebrain neurons, which manifests already in pre-symptomatic MeCP2-deficient female mice and intensifies with disease progression. Stabilizing mitochondrial function by targeted catalase expression proved potentially protective.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.